Applied Therapeutics, Inc. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020
Revenue
License
Research and development services
Total revenue
COSTS AND EXPENSES:
Research and development
General and administrative
Total costs and expenses
LOSS FROM OPERATIONS
OTHER INCOME (EXPENSE), NET:
Interest income
Change in fair value of warrant liabilities
Other expense
Total other expense, net
Net loss
Net loss per share attributable to common stockholders—basic and diluted
Weighted-average common stock outstanding—basic and diluted
Net loss per share attributable to common stockholders - basic
Net loss per share attributable to common stockholders - diluted
Weighted-average common stock outstanding - basic (in shares)
Weighted-average common stock outstanding - diluted (in shares)

Comments